$189 Million is the total value of Soleus Capital Management, L.P.'s 63 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 45.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EPIX | Sell | ESSA PHARMA INC | $12,606,000 | -2.3% | 1,826,980 | -12.3% | 6.68% | -9.2% |
| QDEL | Sell | QUIDEL CORP | $6,746,000 | -2.4% | 30,751 | -0.5% | 3.58% | -9.3% |
| IMMU | Sell | IMMUNOMEDICS INC | $6,485,000 | +53.8% | 76,268 | -35.9% | 3.44% | +43.0% |
| NVCR | Sell | NOVOCURE LTD | $5,830,000 | +74.3% | 52,377 | -7.1% | 3.09% | +62.1% |
| IRMD | Sell | IRADIMED CORP | $4,249,000 | -13.8% | 198,739 | -6.4% | 2.25% | -19.9% |
| ZYME | Sell | ZYMEWORKS INC | $4,156,000 | -72.6% | 89,233 | -78.8% | 2.20% | -74.5% |
| EIGR | Sell | EIGER BIOPHARMACEUTICALS INC | $3,847,000 | -35.4% | 472,558 | -23.8% | 2.04% | -39.9% |
| ALXN | Sell | ALEXION PHARMACEUTICALS INC | $3,442,000 | -39.6% | 30,077 | -40.8% | 1.82% | -43.8% |
| DXCM | Sell | DEXCOM INC | $3,126,000 | -19.2% | 7,583 | -20.6% | 1.66% | -24.9% |
| ZYXI | Sell | ZYNEX INC | $2,060,000 | -53.1% | 118,047 | -33.1% | 1.09% | -56.4% |
| NVRO | Sell | NEVRO CORP | $1,661,000 | -26.0% | 11,926 | -36.6% | 0.88% | -31.2% |
| IONS | Sell | IONIS PHARMACEUTICALS INC | $932,000 | -56.6% | 19,648 | -46.0% | 0.49% | -59.6% |
| STAA | Sell | STAAR SURGICAL CO | $868,000 | -30.9% | 15,346 | -24.9% | 0.46% | -35.8% |
| PODD | Sell | INSULET CORP | $859,000 | +10.6% | 3,632 | -9.2% | 0.46% | +2.7% |
| CRSP | Sell | CRISPR THERAPEUTICS AGnamen akt | $853,000 | -32.5% | 10,200 | -40.7% | 0.45% | -37.3% |
| PCRX | Sell | PACIRA BIOSCIENCES | $613,000 | -4.2% | 10,200 | -16.4% | 0.32% | -11.0% |
| AZN | Sell | ASTRAZENECA PLCsponsored adr | $504,000 | -93.0% | 9,203 | -93.2% | 0.27% | -93.5% |
| FATE | Sell | FATE THERAPEUTICS INC | $388,000 | -65.7% | 9,712 | -70.6% | 0.21% | -68.1% |
| CSTL | Sell | CASTLE BIOSCIENCES INC | $323,000 | -42.8% | 6,269 | -58.2% | 0.17% | -46.9% |
| CNST | Sell | CONSTELLATION PHARMCETICLS I | $218,000 | -78.3% | 10,742 | -67.8% | 0.12% | -79.7% |
| ARVN | Exit | ARVINAS INC | $0 | – | -6,000 | -100.0% | -0.12% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INC | $0 | – | -6,900 | -100.0% | -0.18% | – |
| RAPT | Exit | RAPT THERAPEUTICS INC | $0 | – | -15,100 | -100.0% | -0.25% | – |
| INSP | Exit | INSPIRE MED SYS INC | $0 | – | -5,608 | -100.0% | -0.28% | – |
| ATRS | Exit | ANTARES PHARMA INC | $0 | – | -229,046 | -100.0% | -0.36% | – |
| MASI | Exit | MASIMO CORP | $0 | – | -3,400 | -100.0% | -0.44% | – |
| VAPO | Exit | VAPOTHERM INC | $0 | – | -21,700 | -100.0% | -0.51% | – |
| BHVN | Exit | BIOHAVEN PHARMACTL HLDG CO L | $0 | – | -14,000 | -100.0% | -0.58% | – |
| SILK | Exit | SILK RD MED INC | $0 | – | -27,711 | -100.0% | -0.66% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -127,300 | -100.0% | -1.09% | – |
| HUM | Exit | HUMANA INC | $0 | – | -6,600 | -100.0% | -1.46% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -28,900 | -100.0% | -1.62% | – |
| NARI | Exit | INARI MED INC | $0 | – | -65,817 | -100.0% | -1.82% | – |
| LLY | Exit | LILLY ELI & CO | $0 | – | -20,800 | -100.0% | -1.95% | – |
| AGLE | Exit | AEGLEA BIOTHERAPEUTICS INC | $0 | – | -369,852 | -100.0% | -1.95% | – |
| PRTA | Exit | PROTHENA CORP PLC | $0 | – | -674,603 | -100.0% | -4.02% | – |
| ZYME | Exit | ZYMEWORKS INCput | $0 | – | -327,900 | -100.0% | -6.74% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ESSA PHARMA INC | 16 | Q3 2023 | 10.8% |
| IRADIMED CORP | 16 | Q3 2023 | 5.8% |
| XENON PHARMACEUTICALS INC | 15 | Q3 2023 | 2.9% |
| IVERIC BIO INC | 14 | Q1 2023 | 6.5% |
| SURMODICS INC | 14 | Q3 2023 | 4.7% |
| NATERA INC | 13 | Q3 2023 | 3.9% |
| DEXCOM INC | 13 | Q2 2023 | 4.2% |
| NOVOCURE LTD | 13 | Q3 2023 | 3.4% |
| CRISPR THERAPEUTICS AG | 13 | Q2 2023 | 2.6% |
| LYRA THERAPEUTICS INC | 13 | Q3 2023 | 1.0% |
View Soleus Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Soleus Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.